Delineation of proapoptotic signaling of anthracene-shelled M
Apoptosis
Cisplatin resistance
Collateral sensitivity
Curcumin
Metallosupramolecules
Synergism
Journal
Investigational new drugs
ISSN: 1573-0646
Titre abrégé: Invest New Drugs
Pays: United States
ID NLM: 8309330
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
07
12
2018
accepted:
31
01
2019
pubmed:
9
2
2019
medline:
25
4
2020
entrez:
9
2
2019
Statut:
ppublish
Résumé
Since the introduction of cisplatin into clinical practice a few decades ago, the topic of metal-based drugs has expanded significantly. Recent examples emphasize on metallosupramolecules as an emerging class of compounds with diverse properties. They can trigger unique cellular events in malignant cells or serve as molecular hosts for various biologically active compounds, including anticancer agents. The anthracene-shelled M
Identifiants
pubmed: 30734201
doi: 10.1007/s10637-019-00738-y
pii: 10.1007/s10637-019-00738-y
doi:
Substances chimiques
Anthracenes
0
Antineoplastic Agents
0
Capsules
0
anthracene
EH46A1TLD7
Curcumin
IT942ZTH98
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1117-1126Références
Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level (review). Oncol Rep 10:1663–1682. https://doi.org/10.3892/or.10.6.1663
doi: 10.3892/or.10.6.1663
pubmed: 14534679
Momekov G, Bakalova A, Karaivanova M (2005) Novel approaches towards development of non-classical platinum-based antineoplastic agents: Design of Platinum Complexes Characterized by an alternative DNA-binding pattern and/or tumor-targeted cytotoxicity. Curr Med Chem 12(19):2177–2191. https://doi.org/10.2174/0929867054864877
doi: 10.2174/0929867054864877
pubmed: 16178779
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257. https://doi.org/10.1038/cddis.2013.428
doi: 10.1038/cddis.2013.428
pubmed: 24874729
pmcid: 4047912
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869–1883. https://doi.org/10.1038/onc.2011.384
doi: 10.1038/onc.2011.384
pubmed: 21892204
Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev 64(3):706–721. https://doi.org/10.1124/pr.111.005637
doi: 10.1124/pr.111.005637
pubmed: 22659329
pmcid: 3400836
Sharom FJ (2014) Complex interplay between the P-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function. Front Oncol 4:41. https://doi.org/10.3389/fonc.2014.00041
doi: 10.3389/fonc.2014.00041
pubmed: 24624364
pmcid: 3939933
Patel NR, Pattni BS, Abouzeid AH, Torchilin VP (2013) Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 65(13–14):1748–1762. https://doi.org/10.1016/j.addr.2013.08.004
doi: 10.1016/j.addr.2013.08.004
pubmed: 23973912
Zinzi L, Capparelli E, Cantore M, Contino M, Leopoldo M, Colabufo NA (2014) Small and innovative molecules as new strategy to revert MDR. Front Oncol 4:2. https://doi.org/10.3389/fonc.2014.00002
doi: 10.3389/fonc.2014.00002
pubmed: 24478983
pmcid: 3896858
Wu C-P, Hsieh C-H, Wu Y-S (2011) The emergence of drug transporter-mediated multidrug resistance to Cancer chemotherapy. Mol Pharm 8(6):1996–2011. https://doi.org/10.1021/mp200261n
doi: 10.1021/mp200261n
pubmed: 21770407
Yamasaki M, Makino T, Masuzawa T, Kurokawa Y, Miyata H, Takiguchi S, Nakajima K, Fujiwara Y, Matsuura N, Mori M, Doki Y (2011) Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br J Cancer 104(4):707–713. https://doi.org/10.1038/sj.bjc.6606071
doi: 10.1038/sj.bjc.6606071
pubmed: 21206495
pmcid: 3049584
Kilari D, Guancial E, Kim ES (2016) Role of copper transporters in platinum resistance. World J Clin Oncol 7(1):106–113. https://doi.org/10.5306/wjco.v7.i1.106
doi: 10.5306/wjco.v7.i1.106
pubmed: 26862494
pmcid: 4734932
Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X (2016) Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther 10:1885–1895. https://doi.org/10.2147/DDDT.S106412
doi: 10.2147/DDDT.S106412
pubmed: 27354763
pmcid: 4907638
Matsuo K, Lin YG, Roman LD, Sood AK (2010) Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs 19(11):1339–1354. https://doi.org/10.1517/13543784.2010.515585
doi: 10.1517/13543784.2010.515585
pubmed: 20815774
pmcid: 2962713
Wang X, Guo Z (2013) Targeting and delivery of platinum-based anticancer drugs. Chem Soc Rev 42(1):202–224. https://doi.org/10.1039/c2cs35259a
doi: 10.1039/c2cs35259a
pubmed: 23042411
Zhou H, Wang G, Lu Y, Pan Z (2016) Bio-inspired cisplatin nanocarriers for osteosarcoma treatment. Biomater Sci 4(8):1212–1218. https://doi.org/10.1039/C6BM00331A
doi: 10.1039/C6BM00331A
pubmed: 27315174
Piktel E, Niemirowicz K, Watek M, Wollny T, Deptula P, Bucki R (2016) Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy. J Nanobiotechnology 14(1):39. https://doi.org/10.1186/s12951-016-0193-x
doi: 10.1186/s12951-016-0193-x
pubmed: 27229857
pmcid: 4881065
Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 65(13–14):1866–1879. https://doi.org/10.1016/j.addr.2013.09.019
doi: 10.1016/j.addr.2013.09.019
pubmed: 24120656
pmcid: 24120656
Lewis JEM, Gavey EL, Cameron SA, Crowley JD (2012) Stimuli-responsive Pd
doi: 10.1039/c2sc00899h
Schmidt A, Hollering M, Drees M, Casini A, Kühn FE (2016) Supramolecular: Exo -functionalized palladium cages: fluorescent properties and biological activity. Dalton Trans 45(20):8556–8565. https://doi.org/10.1039/c6dt00654j
doi: 10.1039/c6dt00654j
pubmed: 27126799
Therrien B (2012) Drug delivery by water-soluble organometallic cages. Top Curr Chem 319:35–55. https://doi.org/10.1007/128_2011_272
doi: 10.1007/128_2011_272
pubmed: 21952848
Ahmedova A, Momekova D, Yamashina M, Shestakova P, Momekov G, Akita M, Yoshizawa M (2016) Anticancer potencies of PtII-and PdII-linked M2L4 coordination capsules with improved selectivity. Chem Asian J 11(4):474–477
doi: 10.1002/asia.201501238
Ahmedova A, Mihaylova R, Momekova D, Shestakova P, Stoykova S, Zaharieva J, Yamashina M, Momekov G, Akita M, Yoshizawa M (2016) M
doi: 10.1039/C6DT01801G
pubmed: 27488015
Pinto AC, Moreira JN, Simões S (2011) Combination chemotherapy in Cancer: principles, evaluation and drug delivery strategies. Current Cancer treatment – novel beyond conventional approaches. InTech, Available from: http://www.intechopen.com/books/current-cancer-treatment-novel-beyond-conventional-approaches/combination-chemotherapy-in-cancer-principles-evaluation-and-drug-delivery-strategie . Accessed August 2018
Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58(3):621–681. https://doi.org/10.1124/pr.58.3.10
doi: 10.1124/pr.58.3.10
pubmed: 16968952
Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27–55
doi: 10.1016/0065-2571(84)90007-4
Chou TC (2010) Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 70(2):440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947
doi: 10.1158/0008-5472.CAN-09-1947
pubmed: 20068163
Kishi N, Li Z, Yoza K, Akita M, Yoshizawa M (2011) An M
doi: 10.1021/ja2037029
pubmed: 21707060
Yamashina M, Sei Y, Akita M, Yoshizawa M (2014) Safe storage of radical initiators within a polyaromatic nanocapsule. Nat Commun 5:4662. https://doi.org/10.1038/ncomms5662.
Zhelezova I, Momekov G, Кonstantinov S In vitro models of drug resistance in AML cell lines. In: Pajeva I, Argirova R, Bacvarov K, Boteva D, Burneva N (eds) Bulgarian-German scientific cooperation: past, present and future., Sofia, November 26–28, 2015. Humboldt Union in Bulgaria, pp 166–171